SI9300287A - Process for preparing aryl piperazinyl-heterocyclic compounds - Google Patents

Process for preparing aryl piperazinyl-heterocyclic compounds Download PDF

Info

Publication number
SI9300287A
SI9300287A SI9300287A SI9300287A SI9300287A SI 9300287 A SI9300287 A SI 9300287A SI 9300287 A SI9300287 A SI 9300287A SI 9300287 A SI9300287 A SI 9300287A SI 9300287 A SI9300287 A SI 9300287A
Authority
SI
Slovenia
Prior art keywords
chloro
compound
fluoro
formula
piperzine
Prior art date
Application number
SI9300287A
Other languages
English (en)
Slovenian (sl)
Inventor
Paul Bowles
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25468285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9300287(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of SI9300287A publication Critical patent/SI9300287A/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Lubricants (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Eye Examination Apparatus (AREA)
SI9300287A 1992-08-26 1993-05-28 Process for preparing aryl piperazinyl-heterocyclic compounds SI9300287A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/936,179 US5206366A (en) 1992-08-26 1992-08-26 Process for preparing aryl piperazinyl-heterocyclic compounds

Publications (1)

Publication Number Publication Date
SI9300287A true SI9300287A (en) 1994-03-31

Family

ID=25468285

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9300287A SI9300287A (en) 1992-08-26 1993-05-28 Process for preparing aryl piperazinyl-heterocyclic compounds

Country Status (27)

Country Link
US (1) US5206366A (es)
EP (2) EP0584903B1 (es)
JP (1) JP2742370B2 (es)
KR (1) KR0123441B1 (es)
CN (1) CN1033089C (es)
AT (2) ATE206422T1 (es)
AU (1) AU642836B1 (es)
BR (1) BR9302065A (es)
CZ (1) CZ281893B6 (es)
DE (2) DE69333597T2 (es)
DK (2) DK1029861T3 (es)
EG (1) EG20214A (es)
ES (2) ES2161703T3 (es)
FI (1) FI111641B (es)
HU (1) HU223312B1 (es)
IL (1) IL105622A (es)
MX (1) MX9302813A (es)
MY (1) MY109731A (es)
NO (1) NO300685B1 (es)
NZ (1) NZ247539A (es)
PL (1) PL173840B1 (es)
PT (2) PT1029861E (es)
RU (1) RU2061695C1 (es)
SI (1) SI9300287A (es)
SK (1) SK280584B6 (es)
YU (1) YU48964B (es)
ZA (1) ZA936225B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
WO1996039397A1 (en) * 1995-06-06 1996-12-12 Hoechst Marion Roussel, Inc. Benzisoxazole and indazole derivatives as antipsychotic agents
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
CZ289216B6 (cs) * 1996-05-07 2001-12-12 Pfizer Inc. Trihydrát methansulfonátu 5-(2-(4-(1,2-benzizothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2H-indol-2-onu, farmaceutická kompozice a léčivo na jeho bázi
US5945421A (en) * 1997-08-11 1999-08-31 Warner-Lambert Company Dopamine D4 receptor antagonists
US6040448A (en) * 1997-10-24 2000-03-21 Neurogen Corporation Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
WO1999044608A1 (en) * 1998-03-06 1999-09-10 Astrazeneca Ab New use
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6660858B2 (en) 2001-03-28 2003-12-09 Lion Bioscience Ag 2-aminobenzoxazole derivatives and combinatorial libraries thereof
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
WO2004026864A1 (en) * 2002-09-17 2004-04-01 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004037819A1 (en) * 2002-10-24 2004-05-06 Pfizer Products Inc. Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity
CA2505397A1 (en) * 2002-11-08 2004-05-21 Warner-Lambert Company Llc Phenylalkyl and pyridylalkyl piperazine derivatives
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
AU2003300814A1 (en) 2002-12-04 2004-06-23 Dr. Reddy's Laboratories Inc. Polymorphic forms of ziprasidone and its hydrochloride
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
US20050143396A1 (en) * 2003-04-11 2005-06-30 Hertero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
EP1546146A1 (en) * 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
EP1592688A2 (en) * 2003-12-18 2005-11-09 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
ES2334800T3 (es) * 2004-02-27 2010-03-16 Ranbaxy Laboratories Limited Proceso para la preparacion de ziprasidona.
ITMI20040944A1 (it) * 2004-05-11 2004-08-11 Dinamite Dipharma S P A In For Polimorfo di ziprasidone cloridrato e procedimento per la sua preparazione
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7728136B2 (en) 2004-06-18 2010-06-01 Lupin Limited Method for the preparation of aryl piperazinyl-heterocyclic compounds
WO2006026426A2 (en) * 2004-08-27 2006-03-09 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally
ES2250000B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Procedimiento para la preparacion de ziprasidona.
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
WO2006086779A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Amorphous ziprasidone mesylate
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
MX2007012083A (es) * 2005-04-01 2007-11-20 Warner Lambert Co Tetrahidro-piridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia.
HU230479B1 (hu) * 2006-05-02 2016-07-28 Richter Gedeon Nyrt. Eljárás 5-{2-[4-(1,2-benzizotiazol-3-il)-1-piperazinil]-etil}-6-klór-1,3-dihidro-2H-indol-2-on (Ziprasidon) előállítására
HUP0600868A3 (en) * 2006-11-24 2009-03-30 Richter Gedeon Nyrt 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrogen bromide polimorphs and process for their preparation
US8410268B2 (en) * 2008-03-11 2013-04-02 Alkem Laboratories Limited Process for the preparation of ziprasidone
CA2799154A1 (en) 2010-05-12 2011-11-17 Abbvie Inc. Indazole inhibitors of kinase
PL391810A1 (pl) 2010-07-14 2012-01-16 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Nowe sole ziprasidonu oraz sposoby ich otrzymywania
WO2012020424A1 (en) 2010-08-12 2012-02-16 Arch Pharmalabs Limited A short process for the preparation of ziprasidone and intermediates thereof
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610988A (en) * 1982-04-09 1986-09-09 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(substituted)piperazines useful for alleviating pain
FR2536749A1 (fr) * 1982-11-25 1984-06-01 Cerm Cent Europ Rech Mauvernay (amino-2 ethyl)-6 benzoxazolinones substituees, leur preparation et leurs applications en therapeutique
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride

Also Published As

Publication number Publication date
DE69333597D1 (de) 2004-09-23
JPH06184143A (ja) 1994-07-05
JP2742370B2 (ja) 1998-04-22
HUT65750A (en) 1994-07-28
PT1029861E (pt) 2004-11-30
ES2225015T3 (es) 2005-03-16
FI932012A0 (fi) 1993-05-04
DE69333597T2 (de) 2005-09-15
ES2161703T3 (es) 2001-12-16
MX9302813A (es) 1994-02-28
DE69330853D1 (de) 2001-11-08
HU223312B1 (hu) 2004-05-28
NO931656L (no) 1994-02-28
CZ281893B6 (cs) 1997-03-12
HU9301291D0 (en) 1993-07-28
EG20214A (en) 1997-11-30
BR9302065A (pt) 1994-07-26
EP0584903B1 (en) 2001-10-04
IL105622A0 (en) 1993-09-22
ZA936225B (en) 1995-02-27
CN1083061A (zh) 1994-03-02
DE69330853T2 (de) 2002-05-02
PL173840B1 (pl) 1998-05-29
NO931656D0 (no) 1993-05-06
NZ247539A (en) 1995-09-26
IL105622A (en) 1998-06-15
US5206366A (en) 1993-04-27
KR0123441B1 (ko) 1997-11-24
RU2061695C1 (ru) 1996-06-10
EP0584903A1 (en) 1994-03-02
PT584903E (pt) 2002-02-28
DK1029861T3 (da) 2004-11-15
YU56593A (sh) 1996-07-24
FI111641B (fi) 2003-08-29
MY109731A (en) 1997-05-31
YU48964B (sh) 2003-01-31
PL299002A1 (en) 1994-03-21
FI932012A (fi) 1994-02-27
AU642836B1 (en) 1993-10-28
NO300685B1 (no) 1997-07-07
SK48593A3 (en) 1994-04-06
KR940003952A (ko) 1994-03-14
DK0584903T3 (da) 2001-12-03
SK280584B6 (sk) 2000-04-10
EP1029861B1 (en) 2004-08-18
CN1033089C (zh) 1996-10-23
ATE206422T1 (de) 2001-10-15
ATE273976T1 (de) 2004-09-15
EP1029861A1 (en) 2000-08-23
CZ87793A3 (en) 1994-04-13

Similar Documents

Publication Publication Date Title
SI9300287A (en) Process for preparing aryl piperazinyl-heterocyclic compounds
CA2095587C (en) Process for preparing aryl piperazinyl-hetero-cyclic compounds
FI77855C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 6-fluor-1,4-dihydro-4-oxo-3- kinolinkarboxylsyraderivat.
JP2006028192A (ja) リスペリドンの調製
JPH054983A (ja) イソキノリノン誘導体、その製造方法およびその誘導体を有効成分として含有する５−ｈｔ３ レセプター拮抗剤
FR2476088A2 (fr) Nouveaux derives du nor-tropane, leur procede de preparation et leur application en therapeutique
EP1142885A1 (en) Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives
EP0591027A1 (fr) Dérivés de pipéridine, leur préparation et leur application en thérapeutique
JPH01319487A (ja) イミダゾ［２，１−ｂ］ベンゾチアゾール誘導体及び該化合物を有効成分とする抗潰瘍剤
EP0569387A1 (en) Racemate resolution of trans-2- (2-pyrimidinyl) -7- (hydroxymethyl) octahydro-2H-pyrido [1,2-a] pyrazine.
JPS58167573A (ja) 新規な６−アリ−ル−４，５−ジヒドロ−３（２ｈ）−ピリダジノン、その製法及び用途
JPH0114235B2 (es)
JPH0440348B2 (es)
US5059607A (en) Imidazolyl benzisoquinolines useful as 5-ht3 receptor antagonists
JP3068175B2 (ja) イソチアゾロ〔５，４―ｂ〕ピリジン誘導体
EP1633754B1 (en) Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
JPH01279864A (ja) 新規の１，２―ジヒドロピリド〔３，４―ｂ〕―ピラジン類製造用の中間体
CN114957232B (zh) 一种苯并二氢恶嗪类化合物及其制备方法和抗结核的用途
JPS6130588A (ja) ベンゾ〔ｃ〕〔１，８〕ナフチリジン、その製造方法及びその使用、並びにこれらの化合物を含有する調製剤
JPS6111235B2 (es)
DE3017560A1 (de) 9-amino-6,7-dihydro-4h-pyrido eckige klammer auf 1,2-a eckige klammer zu pyrimidin-4-on-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische kompositionen
JPS5925795B2 (ja) ピリド〔２，３−ｃ〕アクリジン−１−ヒドロキシ−２−カルボン酸及びその誘導体並びにその製法
JPH01319488A (ja) テトラヒドロイミダゾ［２，１−ｂ］ベンゾチアゾール誘導体及び該化合物を有効成分とする抗潰瘍剤
JPS6032790A (ja) １，８−ナフチリジン類
JPS61180788A (ja) チオピラノピリミジン誘導体およびその酸付加塩

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20100127